4DMedical (4DX) Stock Overview
Operates as a medical technology company in the United States and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
4DX Community Fair Values
Create NarrativeSee what 61 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
AU$11.11
FV
63.5% undervalued intrinsic discount598
users have viewed this narrative5users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
4DMedical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$4.06 |
| 52 Week High | AU$7.55 |
| 52 Week Low | AU$0.23 |
| Beta | 2.01 |
| 1 Month Change | 5.45% |
| 3 Month Change | -28.01% |
| 1 Year Change | 1,591.67% |
| 3 Year Change | 444.97% |
| 5 Year Change | 219.69% |
| Change since IPO | 155.35% |
Recent News & Updates
Analysis Article • Jun 20
4DMedical (ASX:4DX) Shares Could Be 59.1% Undervalued After Philips Webinar Interest
Recent attention on 4DMedical (ASX:4DX) has been tied to its participation in a joint webinar with Philips and bioAffinity Technologies on diagnostic and imaging tools for U.S. veterans, alongside a recent move in the share price. See our latest analysis for 4DMedical. The recent webinar news comes on top of strong momentum in 4DMedical’s share price, with a 1 month share price return of 38.41% and a 7 day move of 23.37%. The 1 year total shareholder return is also extremely large, indicating...
Narrative Update • Jun 18
4DX: European AI Lung Imaging Expansion Will Support Higher Future Earnings Multiple
Analysts have kept their fair value estimate for 4DMedical unchanged at A$4.97, with only minor tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions informing the latest price target narrative. What’s in the News for 4DMedical 4DMedical shares fell nearly 9% as the company pursues parallel expansion in the U.S. and Europe, including wider deployment plans for its CT:VQ imaging technology for pulmonary embolism diagnosis.Recent updates
Analysis Article • Jun 20
4DMedical (ASX:4DX) Shares Could Be 59.1% Undervalued After Philips Webinar Interest
Recent attention on 4DMedical (ASX:4DX) has been tied to its participation in a joint webinar with Philips and bioAffinity Technologies on diagnostic and imaging tools for U.S. veterans, alongside a recent move in the share price. See our latest analysis for 4DMedical. The recent webinar news comes on top of strong momentum in 4DMedical’s share price, with a 1 month share price return of 38.41% and a 7 day move of 23.37%. The 1 year total shareholder return is also extremely large, indicating...Narrative Update • Jun 18
4DX: European AI Lung Imaging Expansion Will Support Higher Future Earnings Multiple
Analysts have kept their fair value estimate for 4DMedical unchanged at A$4.97, with only minor tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions informing the latest price target narrative. What’s in the News for 4DMedical 4DMedical shares fell nearly 9% as the company pursues parallel expansion in the U.S. and Europe, including wider deployment plans for its CT:VQ imaging technology for pulmonary embolism diagnosis.Narrative Update • Jun 04
4DX: European AI Lung Imaging Entry Will Support Elevated Future Earnings Multiple
Analysts have nudged their fair value estimate for 4DMedical higher from A$4.47 to A$4.97, pointing to fine tuned assumptions around discount rates, revenue growth, profit margins and future P/E expectations as the key drivers of the updated price target. What's in the News 4DMedical has agreed to acquire Austrian medtech company contextflow, gaining a Vienna based team, European commercial and clinical infrastructure, a CE marked AI lung cancer screening platform and German insurance reimbursement contracts, according to recent news reports.Narrative Update • May 15
4DX: Index Inclusion And European Certification Will Test Elevated Future Earnings Multiple
Analysts have modestly adjusted their price target for 4DMedical to A$4.47, reflecting updated assumptions around a slightly lower discount rate, a very large revenue growth outlook, and a broadly unchanged long term profit margin and future P/E multiple. What's in the News 4DMedical entered a one year contractual engagement with GlaxoSmithKline, in association with Flywheel Exchange, to provide its quantitative lung imaging analytics for pulmonary drug development and clinical research, with commercial terms confidential and described as not individually material (Client Announcements).Narrative Update • Apr 29
4DX: Index Inclusion And European Imaging Rollout Will Test Stretched Future Earnings Multiple
Analysts have raised their price target on 4DMedical to A$4.47 from A$4.13, reflecting updated views on fair value, discount rate assumptions and future P/E expectations. What's in the News 4DMedical entered a one year contractual engagement with GlaxoSmithKline, in association with Flywheel Exchange, to provide proprietary quantitative lung imaging analytics for pulmonary drug development and clinical research, with contract value described as commercially confidential and not individually material (client announcement).Narrative Update • Apr 14
4DX: Index Inclusion Will Intensify Concerns Over Stretched Future Earnings Multiple
Analysts have maintained their A$4.13 price target for 4DMedical, citing only modest adjustments in the discount rate, revenue growth, profit margin and future P/E assumptions as the main reasons for keeping their view unchanged. What's in the News 4DMedical completed a follow on equity offering of A$83.0 million, issuing 14,067,797 ordinary shares at A$5.90 per share with a A$0.236 discount per security, as a subsequent direct listing (company filing).Narrative Update • Mar 31
4DX: Equity Raises And Index Inclusion Will Highlight Stretch In Future Earnings
Analysts have trimmed their 4DMedical price target slightly to A$4.13 from A$4.20, reflecting updated fair value work and a modestly lower future P/E assumption, while revenue growth and margin expectations are broadly unchanged. What's in the News CT:VQ, 4DMedical's non-contrast ventilation perfusion imaging technology, has received CE Mark certification for commercial use in the European Union, allowing the company to pursue one of the largest respiratory imaging markets globally (Key Developments).Narrative Update • Mar 17
4DX: Equity Raise And New CFO Appointment Will Support Balanced Outlook
Analysts have adjusted their price target on 4DMedical to A$4.20, reflecting updated views on the discount rate, revenue growth, profit margin and a higher assumed future P/E multiple. What's in the News 4DMedical completed a follow on equity offering of A$79.063503 million through the issue of 20,806,185 ordinary shares at A$3.80 per share, reflecting a A$0.19 discount per security (Key Developments).Narrative Update • Mar 02
4DX: Equity Raise And New CFO Will Likely Support Balanced Outlook
Analysts have raised their 4DMedical price target from A$3.40 to A$4.20, citing updated assumptions that include revised revenue growth, profit margin and future P/E inputs in their models. What's in the News Completed a follow on equity offering of A$79.063503 million in ordinary shares, issuing 20,806,185 securities at A$3.80 each with a A$0.19 discount per security (Key Developments).Narrative Update • Feb 16
4DX: Equity Raise And New CFO Will Likely Fail To Support Multiple
Analysts have raised their price target on 4DMedical to A$3.40, reflecting adjustments to their fair value estimate, discount rate, expected revenue growth, profit margin and future P/E assumptions. What's in the News 4DMedical completed a follow on equity offering of A$79.063503 million, issuing 20,806,185 ordinary shares at A$3.80 per share with a A$0.19 discount per security (Key Developments).Narrative Update • Feb 02
4DX: Equity Raise Will Likely Fail To Support Elevated Earnings Multiple
Analysts have trimmed their price target on 4DMedical to A$2.73, with the adjustment tied to small updates in discount rate assumptions, revenue growth forecasts, and an improved profit margin outlook. Together, these factors feed into a slightly lower future P/E expectation.Narrative Update • Jan 19
4DX: Equity Raise And CFO Appointment Will Likely Fail To Support Valuation
Analysts have lifted their price target on 4DMedical to A$2.73 from A$2.30, reflecting updated views on fair value, slightly adjusted discount rates and refreshed assumptions around revenue growth, profit margins and future P/E levels. What's in the News 4DMedical completed a follow on equity offering of approximately A$79.1m, issuing 20,806,185 ordinary shares at A$3.80 per share with a A$0.19 discount per security (Key Developments).Narrative Update • Jan 05
4DX: Commercial Momentum And New CFO Will Likely Fail To Justify High Multiple
Analysts have left their price target for 4DMedical broadly unchanged at A$2.30. This reflects only minor tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E rather than a shift in their overall view on the stock.Narrative Update • Dec 19
4DX: Elevated Future Multiple Will Likely Constrain Long Term Share Returns
Analysts have modestly lifted their price target for 4DMedical to 2.30 dollars from 2.30 dollars. This reflects slightly improved profit margin expectations and a marginally lower perceived risk profile that together support a richer, though still elevated, future earnings multiple.Narrative Update • Dec 05
4DX: Higher Long Term Earnings Multiple Will Drive Significant Future Upside
Analysts have nudged their price target on 4DMedical higher from A$2.22 to A$2.30, citing slightly stronger long term revenue growth assumptions and a modestly higher future earnings multiple, despite a small uptick in the discount rate. Valuation Changes The fair value estimate has risen slightly from A$2.22 to A$2.30, reflecting a modest uplift in long term assumptions.Narrative Update • Nov 21
4DX: Margin Expansion And Regulatory Wins Will Drive Significant Future Upside
Analysts have raised their price target for 4DMedical from $1.82 to $2.22. They cite improvements in profit margin forecasts and a lower discount rate as key factors supporting the positive adjustment.Narrative Update • Nov 07
4DX: Continued Revenue Momentum Will Drive Upside Following Regulatory Milestones
Analysts have revised their price target for 4DMedical to $1.82 per share, maintaining the previous valuation. Cautious adjustments to profit margin forecasts were offset by sustained robust revenue growth expectations.Narrative Update • Oct 24
Recent Regulatory Wins And Reimbursement Approvals Will Drive Broader Market Access
Analysts have raised their price target for 4DMedical from $1.43 to $1.82 per share. This change reflects greater optimism in revenue growth and future profitability.Narrative Update • Sep 27
Acquisitions, Philips Partnerships And FDA Approvals Will Expand Market Reach
Upward revisions to 4DMedical’s revenue growth forecasts have driven a higher future P/E multiple, resulting in a substantial increase in the consensus analyst price target from A$0.90 to A$1.43. What's in the News 4DMedical announced FDA 510(k) clearance and CMS reimbursement confirmation for CT:VQ, its non-contrast, ventilation-perfusion imaging software delivered as SaaS, enabling functional lung imaging on standard CT scanners without new hardware.Narrative Update • Sep 03
Acquisitions, Philips Partnerships And FDA Approvals Will Expand Market Reach
Despite a sharp rise in Future P/E and a decline in Net Profit Margin, the consensus analyst price target for 4DMedical has been significantly increased from A$0.725 to A$0.90. Valuation Changes Summary of Valuation Changes for 4DMedical The Consensus Analyst Price Target has significantly risen from A$0.725 to A$0.90.
New Narrative • Apr 04
Acquisitions, Philips Partnerships And FDA Approvals Will Expand Market Reach
Strategic acquisitions, partnerships, and regulatory approvals are poised to enhance market presence, revenue, and net margins through expanded distribution and high-margin services.Analysis Article • Sep 21
Here's Why We're Watching 4DMedical's (ASX:4DX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysis Article • May 08
We're Keeping An Eye On 4DMedical's (ASX:4DX) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Analysis Article • Oct 26
4DMedical Limited's (ASX:4DX) CEO Compensation Is Looking A Bit Stretched At The Moment
Key Insights 4DMedical to hold its Annual General Meeting on 1st of November Total pay for CEO Andreas Fouras includes...Shareholder Returns
| 4DX | AU Healthcare Services | AU Market | |
|---|---|---|---|
| 7D | -11.2% | 12.5% | -0.8% |
| 1Y | 1,591.7% | -25.3% | 1.1% |
Return vs Industry: 4DX exceeded the Australian Healthcare Services industry which returned -25.3% over the past year.
Return vs Market: 4DX exceeded the Australian Market which returned 1.1% over the past year.
Price Volatility
| 4DX volatility | |
|---|---|
| 4DX Average Weekly Movement | 14.8% |
| Healthcare Services Industry Average Movement | 10.2% |
| Market Average Movement | 9.7% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 3.9% |
Stable Share Price: 4DX's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: 4DX's weekly volatility has decreased from 20% to 15% over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 124 | Andreas Fouras | 4dmedical.com |
4DMedical Limited operates as a medical technology company in the United States and Australia. The company engages in the medical research technology and development of a non-invasive respiratory imaging solution using four-dimensional imaging. It offers CT:VQ, non contrast post processing technology; CAC, a non-contrast cardiothoracic risk assessment sotware; CT LVAS, a regional lung function imaging software; IQ-UIP, a state-of-the-art software; LDAf, Patented Parametric Response Mapping (PRM) technology; LDAi, an automated detection of potential emphysema software; LTA provides visualization and quantification of the lung textures; PHA Analysis, a cutting-edge, fully-automated imaging solution; XV LVAS, a lung airflow imaging software; and XV Scanner, a lung function scanner.
4DMedical Limited Fundamentals Summary
| 4DX fundamental statistics | |
|---|---|
| Market cap | AU$2.41b |
| Earnings (TTM) | -AU$172.93m |
| Revenue (TTM) | AU$5.81m |
416.0x
P/S Ratio-14.0x
P/E RatioIs 4DX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4DX income statement (TTM) | |
|---|---|
| Revenue | AU$5.81m |
| Cost of Revenue | AU$472.45k |
| Gross Profit | AU$5.34m |
| Other Expenses | AU$178.26m |
| Earnings | -AU$172.93m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 91.87% |
| Net Profit Margin | -2,976.16% |
| Debt/Equity Ratio | -22.8% |
How did 4DX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/02 08:25 |
| End of Day Share Price | 2026/07/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
4DMedical Limited is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| John Campbell | Jefferies LLC |
| Stephen Blagg | Jefferies LLC |